Role of the prostaglandin D2 receptor CRTH2 in helminth-induced type 2 inflammation in the intestine
前列腺素 D2 受体 CRTH2 在蠕虫引起的肠道 2 型炎症中的作用
基本信息
- 批准号:10228717
- 负责人:
- 金额:$ 43.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAffectAllergicAnti-Inflammatory AgentsBindingBone MarrowCCL4 geneCellsChimera organismCoupledDataDevelopmentDiseaseDopamine D2 ReceptorDrug TargetingDrug usageEpithelialEpithelial CellsEquilibriumGenerationsHelminthsHookwormsImmuneImmune responseImpairmentIn VitroInfectionInflammationInflammatoryInflammatory ResponseInterleukinsIntestinesKnowledgeLeadLipidsLung InflammationLung diseasesLymphoidLymphoid CellModelingMorbidity - disease rateMucinsMucous body substanceMusNippostrongylusOrganoidsParasitesPathologicPathologyPathway interactionsPhenotypePlayPopulationProductionProstaglandin D2ProteinsRoleShapesSignal PathwaySignal TransductionSmall IntestinesSourceSymptomsTestingTh2 CellsWorkbasecytokineexperimental studyfMet-Leu-Phe receptorhelminth infectionimmune activationin vivoinflammatory disease of the intestineinhibitor/antagonistintestinal epitheliumloss of functionmast cellmouse modelnovel therapeuticspreventreceptorresponse
项目摘要
PROJECT SUMMARY
Intestinal helminth parasites infect billions worldwide. Mammalian hosts mount a Type 2 inflammatory
response to infection, which is characterized by immune cell activation and intestinal epithelial cell mucus
secretion that lead to worm expulsion but can also cause pathological excess mucus production. Previous
work has focused on how host-derived proteins called cytokines control Type 2 inflammation, but other factors
such as the lipid prostaglandin D2 (PGD2) are also produced during infection. PGD2 promotes Type 2 allergic
lung inflammation by binding to CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2
cells). However, how the PGD2-CRTH2 pathway interacts with cytokines to regulate Type 2 inflammation
during intestinal helminth infection is unclear. Our preliminary studies revealed that following infection with the
helminth Nippostrongylus brasiliensis, CRTH2-deficient mice had decreased Type 2 immune activation
compared to controls, but surprisingly also had increased epithelial mucin responses and accelerated worm
clearance. This phenotype was also observed in infected bone marrow chimeric mice in which only non-
hematopoietic cells lacked CRTH2, suggesting that the PGD2-CRTH2 pathway suppresses intestinal epithelial
cell mucus responses. Notably, how PGD2 production is regulated is unclear. The epithelial cell-derived
cytokine interleukin (IL)-33, which activates immune cells during helminth infection, elicits PGD2 production
from mast cells in vitro. Thus, IL-33 may activate the PGD2-CRTH2 pathway in vivo. Our preliminary studies
showed that following IL-33 treatment, CRTH2-deficient mice had impaired population expansion of IL-33-
responsive group 2 innate lymphoid cells compared to controls, suggesting that optimal responses to IL-33 in
vivo require CRTH2. Together, these data provoke the central hypothesis that during helminth infection, IL-33
activates the PGD2-CRTH2 pathway to balance Type 2 inflammatory responses, expelling worms efficiently
while limiting pathology. To test this hypothesis, we propose 2 Specific Aims. Aim 1 will test if PGD2 acts
directly on small intestinal epithelial cells to inhibit mucin production during Type 2 inflammation, dependent on
CRTH2, using small intestinal organoid cultures and a new mouse model that allows for deletion of CRTH2
only in intestinal epithelial cells. Aim 2 will test how IL-33 regulates PGD2 production by mast cells to shape
immune responses during Type 2 inflammation, using gain- and loss-of-function experiments, adoptive transfer
approaches, and bone marrow chimeric mice coupled with N. brasiliensis infection. These data will support the
generation of a new paradigm of helminth-induced Type 2 intestinal inflammation that incorporates the effects
of PGD2 and CRTH2, and will inform the development and use of drugs that target the PGD2-CRTH2 pathway
to treat diseases associated with Type 2 inflammation.
项目总结
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Prostaglandin regulation of type 2 inflammation: From basic biology to therapeutic interventions.
- DOI:10.1002/eji.202048909
- 发表时间:2021-10
- 期刊:
- 影响因子:5.4
- 作者:Oyesola OO;Tait Wojno ED
- 通讯作者:Tait Wojno ED
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elia D Tait Wojno其他文献
Epithelial-immune interactions govern type 2 immunity at barrier surfaces
上皮-免疫相互作用在屏障表面调控 2 型免疫。
- DOI:
10.1016/j.coi.2024.102501 - 发表时间:
2024-12-01 - 期刊:
- 影响因子:5.800
- 作者:
Alejandra Lopez Espinoza;Tighe Christopher;Elia D Tait Wojno - 通讯作者:
Elia D Tait Wojno
Elia D Tait Wojno的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elia D Tait Wojno', 18)}}的其他基金
Prostaglandin D2 and its receptor CRTH2 regulate intestinal inflammation and homeostasis
前列腺素 D2 及其受体 CRTH2 调节肠道炎症和体内平衡
- 批准号:
10733671 - 财政年份:2023
- 资助金额:
$ 43.23万 - 项目类别:
The Notch Signaling Pathway Regulates Basophil Responses During Helminth Infection
Notch 信号通路调节蠕虫感染期间嗜碱性粒细胞的反应
- 批准号:
9986356 - 财政年份:2019
- 资助金额:
$ 43.23万 - 项目类别:
The Notch Signaling Pathway Regulates Basophil Responses During Helminth Infection
Notch 信号通路调节蠕虫感染期间嗜碱性粒细胞的反应
- 批准号:
10201422 - 财政年份:2019
- 资助金额:
$ 43.23万 - 项目类别:
Role of the prostaglandin D2 receptor CRTH2 in helminth-induced type 2 inflammation in the intestine
前列腺素 D2 受体 CRTH2 在蠕虫引起的肠道 2 型炎症中的作用
- 批准号:
9986377 - 财政年份:2019
- 资助金额:
$ 43.23万 - 项目类别:
Cytokine regulation of human basophil responses
人类嗜碱性粒细胞反应的细胞因子调节
- 批准号:
8255795 - 财政年份:2012
- 资助金额:
$ 43.23万 - 项目类别:
Cytokine regulation of human basophil responses
人类嗜碱性粒细胞反应的细胞因子调节
- 批准号:
8433040 - 财政年份:2012
- 资助金额:
$ 43.23万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 43.23万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 43.23万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 43.23万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 43.23万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 43.23万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 43.23万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 43.23万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 43.23万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 43.23万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 43.23万 - 项目类别: